GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Newbury Pharmaceuticals AB (OSTO:NEWBRY) » Definitions » Beneish M-Score

Newbury Pharmaceuticals AB (OSTO:NEWBRY) Beneish M-Score : -0.54 (As of Jun. 04, 2024)


View and export this data going back to 2022. Start your Free Trial

What is Newbury Pharmaceuticals AB Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Warning Sign:

Beneish M-Score -0.54 higher than -1.78, which implies that the company might have manipulated its financial results.

The historical rank and industry rank for Newbury Pharmaceuticals AB's Beneish M-Score or its related term are showing as below:

OSTO:NEWBRY' s Beneish M-Score Range Over the Past 10 Years
Min: -2.32   Med: 0.08   Max: 3.2
Current: -0.54

During the past 3 years, the highest Beneish M-Score of Newbury Pharmaceuticals AB was 3.20. The lowest was -2.32. And the median was 0.08.


Newbury Pharmaceuticals AB Beneish M-Score Historical Data

The historical data trend for Newbury Pharmaceuticals AB's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Newbury Pharmaceuticals AB Beneish M-Score Chart

Newbury Pharmaceuticals AB Annual Data
Trend Aug21 Aug22 Aug23
Beneish M-Score
- - 3.20

Newbury Pharmaceuticals AB Quarterly Data
Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.53 0.69 3.20 2.70 -0.54

Competitive Comparison of Newbury Pharmaceuticals AB's Beneish M-Score

For the Drug Manufacturers - Specialty & Generic subindustry, Newbury Pharmaceuticals AB's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Newbury Pharmaceuticals AB's Beneish M-Score Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Newbury Pharmaceuticals AB's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Newbury Pharmaceuticals AB's Beneish M-Score falls into.



Newbury Pharmaceuticals AB Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Newbury Pharmaceuticals AB for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 1.8717+0.528 * 0.6259+0.404 * 0.8733+0.892 * 3.2736+0.115 * 1
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.514+4.679 * 0.100861-0.327 * 4.6587
=-0.54

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Feb24) TTM:Last Year (Feb23) TTM:
Total Receivables was kr22.75 Mil.
Revenue was 3.135 + 11.185 + 2.827 + 5.68 = kr22.83 Mil.
Gross Profit was 1.734 + 4.362 + 1.255 + 2.174 = kr9.53 Mil.
Total Current Assets was kr35.62 Mil.
Total Assets was kr84.13 Mil.
Property, Plant and Equipment(Net PPE) was kr0.00 Mil.
Depreciation, Depletion and Amortization(DDA) was kr1.44 Mil.
Selling, General, & Admin. Expense(SGA) was kr3.16 Mil.
Total Current Liabilities was kr31.42 Mil.
Long-Term Debt & Capital Lease Obligation was kr0.00 Mil.
Net Income was -4.961 + -3.524 + -4.754 + -4.094 = kr-17.33 Mil.
Non Operating Income was 0 + 0 + 0 + 0 = kr0.00 Mil.
Cash Flow from Operations was -7.977 + -5.678 + -3.631 + -8.532 = kr-25.82 Mil.
Total Receivables was kr3.71 Mil.
Revenue was 1.501 + 0.258 + 4.57 + 0.644 = kr6.97 Mil.
Gross Profit was 0.471 + 0.048 + 0.914 + 0.388 = kr1.82 Mil.
Total Current Assets was kr26.19 Mil.
Total Assets was kr77.08 Mil.
Property, Plant and Equipment(Net PPE) was kr0.00 Mil.
Depreciation, Depletion and Amortization(DDA) was kr1.15 Mil.
Selling, General, & Admin. Expense(SGA) was kr1.88 Mil.
Total Current Liabilities was kr6.18 Mil.
Long-Term Debt & Capital Lease Obligation was kr0.00 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(22.751 / 22.827) / (3.713 / 6.973)
=0.996671 / 0.532482
=1.8717

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(1.821 / 6.973) / (9.525 / 22.827)
=0.26115 / 0.417269
=0.6259

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (35.621 + 0) / 84.126) / (1 - (26.19 + 0) / 77.08)
=0.576576 / 0.660223
=0.8733

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=22.827 / 6.973
=3.2736

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(1.151 / (1.151 + 0)) / (1.44 / (1.44 + 0))
=1 / 1
=1

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(3.155 / 22.827) / (1.875 / 6.973)
=0.138214 / 0.268894
=0.514

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((0 + 31.417) / 84.126) / ((0 + 6.179) / 77.08)
=0.373452 / 0.080163
=4.6587

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-17.333 - 0 - -25.818) / 84.126
=0.100861

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Newbury Pharmaceuticals AB has a M-score of -0.54 signals that the company is likely to be a manipulator.


Newbury Pharmaceuticals AB Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Newbury Pharmaceuticals AB's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Newbury Pharmaceuticals AB (OSTO:NEWBRY) Business Description

Traded in Other Exchanges
N/A
Address
Scheeletorget 1, Medicon Village, Lund, SWE, 223 81
Newbury Pharmaceuticals AB is a hybrid pharmaceutical company for specialty prescription drugs, innovation and brands with focus on the Scandinavian markets.

Newbury Pharmaceuticals AB (OSTO:NEWBRY) Headlines

No Headlines